BR100 Increased By (0.75%)
BR30 Increased By (1.08%)
KSE100 Increased By (0.82%)
KSE30 Increased By (0.89%)
AGHA 6.44 Increased By ▲ 0.06 (0.94%)
BECO 4.33 Decreased By ▼ -0.02 (-0.46%)
BML 62.90 Increased By ▲ 0.35 (0.56%)
BOP 31.42 Increased By ▲ 0.03 (0.1%)
CNERGY 11.90 Increased By ▲ 0.17 (1.45%)
CSIL 5.90 Decreased By ▼ -0.01 (-0.17%)
FCCL 62.29 Increased By ▲ 0.58 (0.94%)
FFL 14.87 Increased By ▲ 0.08 (0.54%)
FNEL 1.29 Increased By ▲ 0.05 (4.03%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.90 No Change ▼ 0.00 (0%)
LOTCHEM 24.78 Increased By ▲ 0.09 (0.36%)
MLCF 106.03 Increased By ▲ 2.10 (2.02%)
NBP 174.59 Increased By ▲ 1.27 (0.73%)
NCPL 52.30 Increased By ▲ 0.47 (0.91%)
NPL 55.00 Increased By ▲ 0.97 (1.8%)
OGDC 319.93 Increased By ▲ 4.06 (1.29%)
PACE 9.33 Increased By ▲ 0.07 (0.76%)
PAEL 35.87 Increased By ▲ 0.29 (0.82%)
PIBTL 13.90 Increased By ▲ 0.24 (1.76%)
PPL 228.51 Increased By ▲ 2.44 (1.08%)
PRL 81.91 Increased By ▲ 1.63 (2.03%)
PTC 47.19 Increased By ▲ 0.55 (1.18%)
SSGC 24.01 Increased By ▲ 0.19 (0.8%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.53 Decreased By ▼ -0.02 (-0.26%)
TPL 25.00 Increased By ▲ 0.46 (1.87%)
TPLP 13.15 Increased By ▲ 0.16 (1.23%)
TREET 26.11 Increased By ▲ 0.13 (0.5%)
TRG 53.80 Increased By ▲ 0.47 (0.88%)
World

AstraZeneca finds small clot risk after 1st COVID shot, less after 2nd

  • The EU drug regulator in May advised against a second AstraZeneca shot for people reporting TTS after the first
Published Updated
By

AstraZeneca's COVID-19 vaccine carries a small extra risk of rare blood clots with low platelets after the first dose and no extra risk after the second, a study led and funded by the drugmaker showed on Wednesday, after worries over side-effects.

After the second dose of the vaccine, branded Vaxzevria and invented by Oxford University, the rate was 2.3 per million, comparable to that seen in unvaccinated people, the Anglo-Swedish company added.

AstraZeneca's shot has faced several setbacks, including production delays, and rare cases of severe side-effects, including TTS, which led to several countries restricting or stopping use of the vaccine, probes by regulators and warning labels.

The European Union's (EU) drugs regulator has been looking into cases of TTS since March and has found a possible link to Vaxzevria, and to Johnson & Johnson's single-dose COVID-19 shot. It has, however, maintained that overall benefits of both vaccines outweigh any risks posed by them.

Wednesday's findings evaluated cases reported as of April 30 that occurred within 14 days of receiving the first or second dose, using AstraZeneca's global safety database, it said.

MEDIA ATTENTION

Public focus has been high on the vaccine as it had been hailed as potentially the world's best weapon against the pandemic because it is cheap and easily transportable.

Delayed doses of AstraZeneca jab boost immunity: study

The study said limitations of the analysis included reliance on data provided by healthcare providers and those who got vaccinated, which might lead to under-reporting of cases.

It added that "heightened media attention might have led to event misclassification."

As of the cut-off date, 13 cases of TTS had been identified globally after the second dose in people aged 45 years to 85 years, including eight women. Some 399 cases were reported after the first, the study showed, while data used for the number of doses administered was limited to the EU, European Economic Area, and Britain.

"Unless TTS was identified after the first dose, these results support the administration of the two-dose schedule of Vaxzevria, as indicated, to help provide protection against COVID-19 including against rising variants of concern," AstraZeneca senior executive Mene Pangalos said in a statement.

The EU drug regulator in May advised against a second AstraZeneca shot for people reporting TTS after the first.

Comments

Comments are closed for this article.